|
|
Blood, 15 February 2007, Vol. 109, No. 4, pp. 1495-1502.
Prepublished online as a Blood First Edition Paper on October 12, 2006; DOI 10.1182/blood-2006-06-029298.
 Previous Article | Next Article 
Submitted June 14, 2006
Accepted September 29, 2006
Receptor activator of nuclear factor (NF)- B ligand (RANKL) increases vascular permeability; Impaired permeability and angiogenesis in eNOS-deficient mice
Jeong-Ki Min, Young-Lai Cho, Jae-Hoon Choi, Yonghak Kim, Jeong Hun Kim, Young Suk Yu, Jaerang Rho, Naoki Mochizuki, Young-Myeong Kim, Goo Taeg Oh, and Young-Guen Kwon*
Yonsei University, Korea, Republic of
Kangwon National University, Korea, Republic of
Ewha Womans University, Korea, Republic of
Seoul National University Hospital, Korea, Republic of
Chungnam National University, Korea, Republic of
National Cardiovascular Center Research Institute, Japan
* Corresponding author; email: ygkwon{at}yonsei.ac.kr.
RANKL is emerging as an important regulator of vascular pathophysiology. We here demonstrate a novel role of RANKL as a vascular permeability factor, and a critical role of endothelial nitric oxide synthase (eNOS), in RANKL-induced endothelial function. RANKL increased the vascular permeability and leukocyte infiltration in vivo and caused the breakdown of the blood-retinal barrier in wild type mice but not in eNOS-deficient mice. In vitro, it increased endothelial permeability and reduced VE-cadherin-facilitated endothelial cell-cell junctions in a NO-dependent manner. RANKL also led to the activation of Akt and eNOS, and to NO production in endothelial cells (ECs). These effects were suppressed by the inhibition of TRAF6, phosphoinositide 3'-kinase (PI3K), Akt, or NOS by genetic or pharmacological means. Inhibition of the TRAF6-mediated NO pathway reduced EC migration and capillary-like tube formation in response to RANKL. Moreover, the effects of RANKL on EC sprouting from the aorta, and neovessel formation in both the mouse Matrigel plug assay and corneal micropocket assay, were impaired in eNOS-deficient mice. These results demonstrate that RANKL promotes vascular permeability and angiogenesis by stimulating eNOS by a TRAF6-PI3K-Akt-dependent mechanism. These properties may be relevant to the pathogenesis of angiogenesis-dependent and inflammatory vascular diseases.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Novel function of RANKL: eNOS activator
- Dai Fukumura and Rakesh K. Jain
Blood 2007 109: 1339-1340.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
J. H. Kim, J. H. Kim, Y. S. Yu, K. H. Park, H. J. Kang, H.-Y. Lee, and K.-W. Kim
Antiangiogenic Effect of Deguelin on Choroidal Neovascularization
J. Pharmacol. Exp. Ther.,
February 1, 2008;
324(2):
643 - 647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Viita, J. Markkanen, E. Eriksson, M. Nurminen, K. Kinnunen, M. Babu, T. Heikura, S. Turpeinen, S. Laidinen, T. Takalo, et al.
15-Lipoxygenase-1 Prevents Vascular Endothelial Growth Factor A- and Placental Growth Factor-Induced Angiogenic Effects in Rabbit Skeletal Muscles via Reduction in Growth Factor mRNA Levels, NO Bioactivity, and Downregulation of VEGF Receptor 2 Expression
Circ. Res.,
February 1, 2008;
102(2):
177 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kiechl, G. Schett, J. Schwaiger, K. Seppi, P. Eder, G. Egger, P. Santer, A. Mayr, Q. Xu, and J. Willeit
Soluble Receptor Activator of Nuclear Factor-{kappa}B Ligand and Risk for Cardiovascular Disease
Circulation,
July 24, 2007;
116(4):
385 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
